US20050196450A1 - Method and composition for burned skin - Google Patents

Method and composition for burned skin Download PDF

Info

Publication number
US20050196450A1
US20050196450A1 US10/791,782 US79178204A US2005196450A1 US 20050196450 A1 US20050196450 A1 US 20050196450A1 US 79178204 A US79178204 A US 79178204A US 2005196450 A1 US2005196450 A1 US 2005196450A1
Authority
US
United States
Prior art keywords
composition
ethyl
ammonium hydroxide
isopropyl alcohol
impede
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/791,782
Other languages
English (en)
Inventor
Elka Touitou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/791,782 priority Critical patent/US20050196450A1/en
Assigned to YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM reassignment YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TOUITOU, ELKA
Priority to JP2007501445A priority patent/JP5198846B2/ja
Priority to PCT/IL2005/000249 priority patent/WO2005084632A1/fr
Priority to US10/591,687 priority patent/US20070224272A1/en
Priority to EP05709143.1A priority patent/EP1720534B1/fr
Priority to AU2005219045A priority patent/AU2005219045B2/en
Priority to CA002557968A priority patent/CA2557968A1/fr
Publication of US20050196450A1 publication Critical patent/US20050196450A1/en
Priority to IL177793A priority patent/IL177793A/en
Priority to US12/831,349 priority patent/US8784892B2/en
Priority to JP2012172974A priority patent/JP2012236845A/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • compositions, methods and delivery systems for application on burns and surrounding tissue wherein said composition comprise ammonium hydroxide (or ammonium bicarbonate) and /or 15-70% volatile short chain mono-alcohols
  • Burned skin could be a result of infliction produced by heat, light, UV rays, X-rays, Laser, Infrared rays, friction, abrasion, cold, liquid nitrogen.
  • compositions containing steroidal anti-inflammatories, non-steroidal anti-inflammatories, as well as “natural” anti-inflammatories, such as extract of plants such as aloe vera, have been used.
  • the main objectives are to relieve pain, help prevent contamination, eliminate the source of heat and stop the burn progress.
  • FIG. 2 demonstrates measurement of depth dermal microvascular destruction 24 hours after burn infliction: Animals have been treated immediately after infliction with carbopol gels containing 4% ammonium hydroxide 10% aqueous solution and 20, 30, 50 and 63% w/w ethanol and 1 hour after infliction with a gel containing 30% ethanol. The results were compared with untreated inflicted rats. The depth parameter was measured in rats sacrificed 3, 6, and 24 hours after burn infliction.
  • FIG. 3 shows histological parameters from skin sections 24 hours after burn infliction.
  • the rats were treated immediate after infliction with gels containing 20, 30, 50 and 60% ethanol.
  • FIG. 4 shows histological parameters from skin sections, 24 hours after burn infliction.
  • the rats were treated immediate after infliction with liquid sprays containing 20, 30, 50 and 60% ethanol.
  • the invention provides a composition and use thereof for treating membrane/organ/ burned, friction inflicted skin comprising ethyl or isopropyl alcohol in a concentration of 1 5-70%w/w.
  • the invention provides a composition and use thereof for treating burned skin /membrane/organ comprising ammonium hydroxide.
  • the invention provides a delivery system and use thereof for treating burned skin /membrane/organ comprising a polymer matrix and ammonium hydroxide and ethyl or isopropyl alcohol wherein the ethyl or isopropyl alcohol is in a concentration of 20-60%W/W.
  • the invention provides a composition comprising ethanol from 20-60% w/w, polyacrylate polymer from 0.05%-10%, ammonium hydroxide from 0.1-10%, water from 30-89% to be applied on burned skin and surrounding area, to treat and/ or impede progression and or impede development of burns.
  • the invention provides a Composition comprising ethanol from 25-60% w/w, polyacrylate polymer from 0.05%-10%w/w triethanolamine from 0.1-6%, water from 30-74%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a composition comprising ethanol from 15-60% w/w, polyacrylate polymer from 0.05%-5%, ammonium hydroxide from 0.1-10%, urea from 0.05 to 5% and water from 30-84%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a composition comprising ethanol from 15-70% w/w, cellulose derivative (ethyl, methyl, hydroxymethyl, hydroxyethyl, hydroxypropyl or mixtures of) polymer from 0.05%-20%, and water from 30-84%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • cellulose derivative ethyl, methyl, hydroxymethyl, hydroxyethyl, hydroxypropyl or mixtures of
  • the invention provides a composition
  • a composition comprising ethanol from 15-70% w/w, cellulose derivative (ethyl, methyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, mixtures of) polymer from 0.05%-20%, a hydroxide from 0.1-10%, and water from 30-84%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a composition
  • a composition comprising ethanol from 15-70% w/w, cellulose derivative (ethyl, methyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, mixtures of) polymer from 0.05%-20%, an alkaline agent from 0.1-10%, and water from 30-84%, to be applied on burned, inflicted skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a method for treating and/or impeding progression and or impeding development of burns comprising the step of adding to the burned, inflicted area a composition comprising ethyl or isopropyl alcohol in a concentration of 15-70%w/w.
  • the invention provides a method for treating and/or impeding progression and or impeding development of burns comprising the step of adding to the burned, inflicted area a composition comprising ethyl or isopropyl alcohol in a concentration of 15-70%w/w being a vehicle for compounds for burn treatments.
  • the invention provides a method for treating and/or impeding progression and or impeding development of burns comprising the step of adding a composition to the burned, inflicted area comprising ammonium hydroxide.
  • the invention provides a method for treating and/or impede progression and or impede development of burns comprising the step of adding to the burned area a composition comprising ammonium hydroxide and ethyl and/or isopropyl alcohol wherein the ethyl and/or isopropyl alcohol is in a concentration of 20-60%w/w.
  • the invention provides a composition for treating burned skin /membrane/organ comprising ethyl or isopropyl alcohol in a concentration of 20-60%w/w.
  • the invention provides a composition for treating burned, inflicted skin /membrane/organ comprising ammonium hydroxide.
  • the invention provides a delivery system and use thereof for treating burned skin /membrane/organ comprising a polymer matrix and ammonium hydroxide and ethyl or isopropyl alcohol, wherein the ethyl or isopropyl is in a concentration of 15-70%w/w.
  • the invention provides a composition comprising ethanol from 20-70% w/w, polyacrylate polymer from 0.05%-5%, ammonium hydroxide from 0.1-10%, water from 30-80% to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a composition comprising ethanol from 25-60% w/w, polyacrylate polymer from 0.05%-5%w/w triethanolamine from 0.1-6%, water from 30-74%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a composition comprising ethanol from 15-70% w/w, polyacrylate polymer from 0.05%-5%, ammonium hydroxide from 0.1-10%, urea from 0.05 to 5% and water from 30-84%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a method for treating and/or impeding progression and or impeding development of burns comprising the step of adding to the burned area a composition comprising ethyl or isopropyl alcohol in a concentration of 15-70% w/w.
  • the invention provides a method for treating and/or impedes progression and or impedes development of burns comprising the step of adding a composition to the burned area comprising ammonium hydroxide.
  • the invention provides a method for treating and/or impede progression and or impede development of burns comprising the step of adding to the burned area a composition comprising ammonium hydroxide and ethyl and/or isopropyl alcohol wherein the ethyl and/or isopropyl is in a concentration of 20-70%W/W.
  • the invention provides a method for treating and/or impeding progression and or impeding development of burns comprising the step of adding to the burned area a delivery system comprising polymer matrix and ethyl or isopropyl alcohol in a concentration of 20-70% w/w.
  • the invention provides a method for treating and/or impedes progression and or impedes development of burns comprising the step of adding a delivery system comprising polymer matrix and ammonium hydroxide.
  • the invention provides a method for treating and/or impede progression and/or impede development of burns comprising the step of adding to the burned area a delivery system comprising a polymer matrix ammonium hydroxide and ethyl and/or isopropyl alcohol wherein the ethyl and/or isopropyl is in a concentration of 20-70%w/w.
  • the invention provides a method for treating and/or impede progression and/or impede development of burns comprising the step of adding to the burned area a composition comprising ethanol from 10-70% w/w, polyacrylate polymer from 0.05%-5%, ammonium hydroxide from 0.1-10%, water from 30-84% to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a method for treating and/or impede progression and/or impede development of burns comprising the step of adding to the burned area a composition comprising ethanol from 25-70% w/w, polyacrylate polymer from 0.05%-5%w/w triethanolamine from 0.1-6%, water from 30-84%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a method for treating and/or impede progression and or impede development of burns comprising the step of adding to the burned area a composition comprising ethanol from 15-70% w/w, polyacrylate polymer from 0.05%-5%, ammonium hydroxide from 0.1-10%, urea from 0.05 to 5% and water from 30-84%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • a method for inhibiting the rejection of skin implants in a subject in need comprising the step of contact the inflicted area and/or the implant with an effective amount of the composition of the invention.
  • the invention provides a method for inhibiting the rejection of skin implants in a subject in need comprising the step of contact the inflicted area and/or the implant with an effective amount of a composition comprising ethyl and/or isopropyl alcohol, wherein the ethyl and/or isopropyl alcohol is in a concentration of 15-70%.
  • the invention provides a method for inhibiting the rejection of skin implants in a subject in need comprising the step of contact the inflicted area and/or the implant with an effective amount of a composition comprising ammonium hydroxide.
  • the invention provides a method for inhibiting the rejection of skin implants in a subject in need comprising the step of contact the inflicted area and/or the implant with an effective amount of a composition comprising ammonium hydroxide and ethyl or isopropyl alcohol, wherein the ethyl and/or isopropyl alcohol is in a concentration of 15-70%.
  • the invention provides a method for reducing the level of a cytokine, interleukin, tumor necrosis factor, IL1 or IL6 in an inflicted skin area comprising the step of contact the inflicted or preinflicted area with an effective amount of a composition comprising ethyl and/or isopropyl alcohol, wherein the ethyl and/or isopropyl alcohol is in a concentration of 15-70%.
  • the invention provides a method for reducing the level of a cytokine, interleukin, tumor necrosis factor, IL1 or IL6 in an inflicted skin area comprising the step of contact the inflicted or preinflicted area with an effective amount of a composition comprising ammonium hydroxide.
  • the invention provides a method for reducing the level of a cytokine, interleukin, tumor necrosis factor, IL 1 or IL6 in an inflicted skin area comprising the step of contact the inflicted or preinflicted area with an effective amount of a composition comprising ammonium hydroxide and ethyl or isopropyl alcohol, wherein the ethyl and/or isopropyl alcohol is in a concentration of 15-70%.
  • compositions as well as delivery systems comprising volatile short chain alcohols such as ethyl or isopropyl alcohol in a concentration of 15-70% w/w alone, or in combination with ammonium hydroxide, applied on burns, skin, surrounding skin, membrane, organ, before or after burn stimulus could impede wound development.
  • volatile short chain alcohols such as ethyl or isopropyl alcohol in a concentration of 15-70% w/w alone, or in combination with ammonium hydroxide
  • composition for treating burned skin /membrane/organ comprising ethyl or/and isopropyl alcohol in a concentration of 20-70%w/w.
  • the invention provides a composition for treating burned skin /membrane/organ comprising ammonium hydroxide.
  • ammonium hydroxide is in concentrations from 0.01% to 10% w/w.
  • the invention is directed to a composition for treating burned skin /membrane/organ comprising ammonium hydroxide and ethyl and/or isopropyl alcohol wherein the ethyl and/or isopropyl alcohol is in a concentration of 20-70%.
  • the composition may comprise ammonium hydroxide is in concentrations from 0.01% to 10% w/w.
  • the composition may comprise ammonium hydroxide is in concentrations from 0.01% to 0.1% w/w.
  • the composition may comprise ammonium hydroxide is in concentrations from 0.01% to 0.5% w/w.
  • the composition may comprise ammonium hydroxide is in concentrations from 0.01% to 1% w/w.
  • the composition may comprise ammonium hydroxide is in concentrations from 0.01% to 0.5% w/w.
  • the composition may comprise ammonium hydroxide is in concentrations from 0.01% to 1% w/w.
  • the composition may comprise ammonium hydroxide is in concentrations from 1% to 5% w/w.
  • the composition may comprise ammonium hydroxide is in concentrations from 5% to 10% w/w.
  • the composition may comprise ethyl alcohol or/ and isopropyl alcohol at concentrations of 20-40%w/w.
  • the composition may comprise ethyl alcohol or/ and isopropyl alcohol at concentrations of 40-70%w/w.
  • the concentration of ethyl and/or isopropyl is about 30%.
  • the concentration of ethyl and/or isopropyl is about 25%.
  • the concentration of ethyl and/or isopropyl is about 20%.
  • the concentration of ethyl and/or isopropyl is about 35%.
  • the concentration of ethyl and/or isopropyl is about 40%.
  • the concentration of ethyl and/or isopropyl is about 45%.
  • the concentration of ethyl and/or isopropyl is about 50%.
  • composition of the invention further comprises urea in concentrations from 0.05% to 5% w/w.
  • composition of the invention further comprises urea in concentrations from 0.05% to 10% w/w.
  • composition of the invention further comprises ethanolamine in concentrations from 0.01% to 5% w/w.
  • the ethanol amine may be, for example without limitation, triethanolamine.
  • a delivery system for treating burned skin/membrane/mucosa, organ comprising a polymer matrix and ethyl or/and isopropyl alcohol in a concentration of 20-70%.
  • the invention provides a delivery system for treating burned skin /membrane/organ comprising ammonium hydroxide and a polymer matrix.
  • ammonium hydroxide is in concentrations from 0.01% to 10% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 0.1% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 0.5% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 1% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 0.5% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 1% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 1%-5% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 5%-10% w/w.
  • the invention provides an aqueous delivery system for treating burned skin /membrane/organ comprising ammonium carbonate and a polymer matrix.
  • the invention provides an aqueous delivery system for treating burned skin /membrane/organ comprising ammonium carbonate.
  • the concentration of the ammonium carbonate in the delivery system is from 0.01% to 10% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 1% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 0.1% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 0.5% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 1% w/w
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 0.5% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 0.01% to 1% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 1%-5% w/w.
  • the delivery system may comprise ammonium hydroxide is in concentrations from 5%-I0% w/w.
  • the invention is directed to a delivery system for treating burned skin /membrane/organ comprising ammonium hydroxide and ethyl and/or isopropyl alcohol, wherein the ethyl and/or isopropyl is in a concentration of 20-60% w/w.
  • the concentration of the ethyl and/or isopropyl is from 30-50%.
  • the concentration of ethyl and/or isopropyl is about 30%.
  • the concentration of ethyl and/or isopropyl is about 25%.
  • the concentration of ethyl and/or isopropyl is about 20%.
  • the concentration of ethyl and/or isopropyl is about 35%.
  • the concentration of ethyl and/or isopropyl is about 40%.
  • the concentration of ethyl and/or isopropyl is about 45%.
  • the concentration of ethyl and/or isopropyl is about 50%.
  • the ethyl alcohol and/or isopropyl alcohol may be slowly released from the delivery system or the composition.
  • each of the composition of the invention may comprise an alkalizing agent.
  • ammonium hydroxide may be slowly released from the delivery system or the composition.
  • the polymer of the invention is selected from methylcelluose, ethylcellulose, polyacrylate, acrylates, carbomers, chitin, guar, chitozan, PVP, PVA, gums, sylastic, hydroxypropylcellulose and other cellulose derivatives, Eudragits and such, pectines, hyaluronic acid, hyaluronates, gelatin and derivatives, agar, adhesives or mixture thereof.
  • composition or the delivery system further comprising plant extracts/tinctures/oils/macerates such is arnica, plantago, equisetum, lavender, joubarbe, hamamelis, urtica, calendula, daucus, symphytum, sangui sorba, symphytum, aloe vera, roman chamomile, tea tree, witch hazel, mameluca.
  • plant extracts/tinctures/oils/macerates such is arnica, plantago, equisetum, lavender, joubarbe, hamamelis, urtica, calendula, daucus, symphytum, sangui sorba, symphytum, aloe vera, roman chamomile, tea tree, witch hazel, mameluca.
  • composition or the delivery system of the invention may be in a form of gel, cream, emulsion, lotion, suspension, liposomes, ethosomes, microcapsules, microspheres, bandage, perforated bandage, burn dressing, patch, spray, bath, brushing, douches, aerosols, jet aerosols, foams, used as such or by means of devices.
  • the treatment is a one stage treatment by compositions/devices that stop burn progression and facilitate healing (re-epithelization, re-vascularisation, etc.
  • the treatment may comprise two stage treatment: Stage I—treatment for impeding/ stopping wound formation/ burn progression/burn development; Stage II—treatment for healing—re-epithelization.
  • the invention provides delivery systems that could impede wound development, which comprise short chain volatile alcohols such as ethanol and isopropyl alcohol with or without additional agents, applied on burned skin, surrounding skin, membrane or organ, before or after burn stimulus.
  • short chain volatile alcohols such as ethanol and isopropyl alcohol
  • composition or the delivery system may further include other agents, such as for example without limitation, a antibiotic, a plant extract, a local anesthetic.
  • the composition can also contain antimicrobials, including antibiotics, sulpha derivatives, silver sulphadiazine and mafenide, antifungal, iodine anti-viral compounds and other which may complement or supplement the activity of the basic composition.
  • antimicrobials including antibiotics, sulpha derivatives, silver sulphadiazine and mafenide, antifungal, iodine anti-viral compounds and other which may complement or supplement the activity of the basic composition.
  • Suitable antibiotics include tetracycline, polymyxin, erythromycin, bacitracin, gentamycin, vincomycin, or other antibiotics used in or systemic administration, including over-the-counter formulations.
  • useful antifungal include tolnaftate, nystatin, micatin.
  • antivirals examples include interferon, either natural or recombinant, as well as nucleoside analogs, e.g., acyclovir.
  • Counter-irritants such as camphor and menthol, drying agents such as benzyl alcohol, resorcinol and phenol, and astringents such as zinc sulfate and tannic acid can also be added to the composition as can other types of agents such as sunscreens, emollients, preservatives, fragrances, antioxidants, color additives, lubricants, moisturizers or drying agents.
  • a sunscreen e.g., PABA
  • PABA can be added to the formula since it is known that burns can be caused by ultraviolet radiation.
  • the composition or the delivery system may include Tea Tree Blend.
  • Tea Tree Blend is a mixture of terpenes and terpinols that are generally naturally occurring, but can be synthetically prepared.
  • the terpene and terpinol compounds can be obtained either as pure compounds derived from the natural oils or as mixtures of components derived from plants of Melaleuca alternifolia, Melaleuca lineariifolia, Melaleuca leucadendron, Eucalyptus longirostris and closely related species.
  • a local anesthetic may be added.
  • the anesthetic is preferably selected from the group consisting of esters, amides, ethers, and combinations thereof and, in particular, anesthetics and other anesthetics which may be formulated in accordance with the preferred embodiments of the present invention and applied, including procaine, chloroprocaine, tetracaine, propoxycaine, benzocaine, cocaine, proparacaine, bupivacaine, dibucaine, etidocaine, lidocaine, mepivacaine, prilocaine, dyclonine, promazine and combinations thereof.
  • Antiinflammatory actives useful in accordance with the present invention include steroidal actives such as hydrocortisone as well as non-steroidal actives including propionic derivatives; acetic acid derivatives; biphenylcarboxylic acid derivatives; fenamic acid derivatives; and oxicams.
  • antiinflammatory actives include without limitation acetominaphen, diclofenac, ibuprofen, acetaminophen, indomethacin, oxaprozin, pranoprofen, benoxaprofen, bucloxic acid, elocon; and mixtures thereof.
  • Vitamin actives which may be used in accordance with the present invention include vitamin A and derivatives, including retinoic acid, retinyl aldehyde, retin A, retinyl palmitate, adapalene, and beta-carotene; vitamin B (panthenol, provitamin B5, panthenic acid, vitamin B complex factor); vitamin C (ascorbic acid and salts thereof) and derivatives such as ascorbyl palmitate; vitamin D including calcipotriene (a vitamin D3 analog) vitamin E including its individual constituents alpha-, beta-, gamma-, delta-tocopherol and cotrienols and mixtures thereof and vitamin E derivatives including vitamin E palmitate, vitamin E linolate and vitamin E acetate; vitamin K and derivatives; vitamin Q (ubiquinone) and mixtures thereof
  • the composition may also contain one or more additional agents, including, buffering agents, surfactants, antioxidants, permeation enhancing agents, preservatives, parabens, coloring agents, fragrances, lubricants, moisturizers, sunscreens, drying agents and the like and, more specifically, may include ingredients such as stearic acid, borax, eucalyptus oil, beeswax..
  • additional agents including, buffering agents, surfactants, antioxidants, permeation enhancing agents, preservatives, parabens, coloring agents, fragrances, lubricants, moisturizers, sunscreens, drying agents and the like and, more specifically, may include ingredients such as stearic acid, borax, eucalyptus oil, beeswax.
  • the surfactant may be selected from the group consisting of anionic, nonionic, and cationic surfactants and combinations thereof.
  • Suitable ionic surfactants include anionic surfactants such as monovalent salts, e.g., sodium and potassium salts of alkyl, aryl and alkyl-aryl sulfates and sulfonates, particularly those with from about 8 to 22 carbon atoms, and cationic surfactants, such as quaternary ammonium salts.
  • Suitable non-ionic surfactants include polyethylene oxide adducts of fatty alcohols, e.g., alkylated polyoxyethylenes, alkylated polyoxyethylene-polyoxypropylene copolymers, and the surfactant nonoxynol, lauramide DEA.
  • cationic surfactants may be used, alone.
  • An example is trimethyldodecylammonium chloride, a positively charged quaternary ammonium complex that has antimicrobial characteristics.
  • Nonionic surfactants such as polysorbates, nonoxynol, polyoxyethylene alkyl ethers, polyoxyethylene alkyl ethers, sorbitan esters.
  • Other common nonionic surfactants include polyoxyethylenes amines and polyoxyethylenes amides, polyoxyethylene-polyoxypropylene copolymers, alkyl sorbitols.
  • composition of the invention can be prepared in almost any relatively inert carrier.
  • the formulation could take several forms, e.g., cream, gel, spray, ointment, “Chapstick” and solution forms.
  • Each of these formulations may contain the two active ingredients as well as microorganism growth inhibitors (preservatives).
  • Many such carriers are routinely used and can be obtained by reference to pharmaceutical texts. Examples include polyethylene glycols (PEG), polypropylene copolymers (Pluronics), and some water soluble gels.
  • Thickeners could include natural and synthetic types.
  • the thickeners used can include but are not limited to xanthan, karaya, guar gum, clay tragacanth various polyssacharide materials such as starches.
  • the thickeners can be present in an amount of about 0 parts to about 5 parts.
  • Preservative or preservatives are selected from the group consisting of phenoxyethanol, methylparaben, propylparaben, benzyl alcohol, benzoic acid, sodium benzoate, potassium benzoate, sorbic acid, sodium sorbate, potassium sorbate and phenylethyl alcohol.
  • moisturizer Another ingredient, which may be formulated with the compositions of the present invention, is a moisturizer.
  • a “moisturizer” is an ingredient, which promotes the retention of water to the surface area of the human body skin.
  • the term moisturizer as used herein includes both components that deliver water to the skin, also commonly referred to in the art as “humectant”.
  • Moisturizers that may used in accordance with the present invention include without limitation polyhydroxy alcohols, including glycerol, butylene glycol, hexylene glycol, propylene glycol, tetraglycol, sorbitol and the like; lactic acid and lactate salts, such as sodium or ammonium salts; C.sub.3 and C.sub.6 diols and triols including hexylene glycol, 1,4 dihydroxyhexane, 1,2,6-hexane triol; aloe vera in any of its forms, for example aloe vera gel; sugars and starches; sugar and starch derivatives, for example alkoxylated glucose; hyaluronic acid; lactamide monoethanolamine; acetamide monoethanolamine; glycolic acid; alpha and beta hydroxy acids (e.g. lactic, glycolic salicylic acid); glycerin; panthenol; urea; vaselin; natural oils; oils and waxes (see
  • a further ingredient, which may be formulated with the compositions of the present invention, is an emollient.
  • Emollients are used to add or replace lipids and natural oils to the surface area of the human body.
  • the term emollient as used herein is intended to include conventional lipids (for example, oils, waxes, lipids and other water insoluble components) and polar lipids (lipids which have been modified in order to increase water solubility typically through esterfication of a lipid to a hydrophilic moiety for example hydroxy groups, carbonyl groups and the like).
  • Emollients which may be used in the present invention may be selected from the group consisting of natural oils and plant-derived and essential oils, esters, silicone oils, polyunsaturated fatty acids, lanoline and its derivatives and petrochemicals.
  • Natural oils which may be used in accordance with the present invention may be obtained from sesame; soybean; apricot kernel; palm; peanut; safflower; coconut; olive; cocoa butter; palm kernel; shea butter; sunflower; almond; avocado; borage; carnauba; hazel nut; castor; cotton seed; evening primrose; orange roughly; rapeseed; rice bran; walnut; wheat germ; peach kernel; babassu; mango seed; black current seed; jojoba; macadamia nut; sea buckthorn; sasquana; tsubaki; mallow; meadow foam seed; coffee; emu; mink; grape seed; thistle; tea tree; pumpkin seed; kukui nut; and mixtures thereof.
  • Esters which may be used. Examples of these materials include isopropyl palmitate; isopropyl myristate; isopropyl isononate; C12/C14 benzoate ester (also known as Finesolve); sorbitan palmitate, sorbitan oleate; sucrose palmitate; sucrose oleate; isostearyl lactate; sorbitan laurate; lauryl pyrrolidone carboxylic acid; panthenyl triacetate; and mixtures thereof
  • emollients include silicone oils, including non-volatile and volatile silicones.
  • silicone oils that may be used in the compositions of the present invention are dimethicone; cyclomethycone; dimethycone-copolyol; aminofunctional silicones; phenyl modified silicones; alkyl modified silicones; dimethyl and diethyl polysiloxane; mixed C1-C30 alkyl polysiloxane; and mixtures thereof.
  • a yet further useful group of emollients which may be formulated in accordance with the present invention, are lanolin and lanolin derivatives for example lanolin esters.
  • ingredients mentioned herein are generally defined as emollients they may also possess other properties such as moisturization or other conditioning properties (see under: Moisturizers, hereinbefore mentioned).
  • the composition may comprise ethanol from 20-60% w/w, polyacrylate polymer from 0.05%-5%, ammonium hydroxide from 0.1-10%, water from 30-79% to be applied on burned skin and surrounding area, to treat/impede progression/ impede development of burns (produced by heat, cold, light, u v rays, x rays, Laser, Infrared Rays, liquid nitrogen).
  • the composition may comprise ethanol from 25-60% w/w, polyacrylate polymer from 0.05%-5%w/w triethanolamine from 0.1-6%, water from 30-75%, to treat/impede progression/impede development of burns (produced by heat, cold, light, UV rays, X-Rays, Laser, Infrared Rays, friction, abrasion, liquid nitrogen).
  • the composition may comprise ethanol from 15-60% w/w, polyacrylate polymer from 0.05%-5%, ammonium hydroxide from 0.1-10%, urea from 0.05 to 5% and water from 30-84%, to treat/impede progression/impede development of burns (produced by heat, cold, light, UV rays, X-Rays, Laser, Infrared Rays, liquid nitrogen).
  • the invention provides use of the composition described hereinabove for treating and/or impedes progression and/or impedes development of burns.
  • the invention provides a method for treating and/or impede progression and/or impede development of burns comprising the step of adding to the burned area a composition comprising ethyl or isopropyl alcohol in a concentration of 20-60% w/w.
  • the invention provides a method for treating and/or impedes progression and/or impedes development of burns comprising the step of adding a composition to the burned area comprising ammonium hydroxide.
  • the invention provides a method for treating and/or impede progression and/or impede development of burns comprising the step of adding to the burned area a composition comprising ammonium hydroxide and ethyl and/or isopropyl alcohol wherein the ethyl and/or isopropyl is in a concentration of 20-60% w/w.
  • the invention provides a method for treating and/or impede progression and/or impede development of burns comprising the step of adding to the burned area a delivery system comprising polymer matrix and ethyl or isopropyl alcohol in a concentration of 20-60%w/w.
  • the invention provides a method for treating and/or impedes progression and/or impedes development of burns comprising the step of adding a delivery system comprising polymer matrix and ammonium hydroxide.
  • the invention provides a method for treating and/or impede progression and/or impede development of burns comprising the step of adding to the burned area a delivery system comprising a polymer matrix ammonium hydroxide and ethyl and/or isopropyl alcohol wherein the ethyl and/or isopropyl is in a concentration of 20-60%w/w.
  • the invention provides a method for treating and/or impede progression and/or impede development of burns comprising the step of adding to the burned area a composition comprising ethanol from 20-60% w/w, polyacrylate polymer from 0.05%-5%, ammonium hydroxide from 0.1-10%, water from 30-80% to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a method for treating and/or impede progression and or impede development of burns comprising the step of adding to the burned area a composition comprising ethanol from 25-60% w/w, polyacrylate polymer from 0.05%-5%w/w triethanolamine from 0.1-6%, water from 30-74%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • the invention provides a method for treating and/or impeding progression and/or impeding development of burns comprising the step of adding to the burned area a composition comprising ethanol from 15-60% w/w, polyacrylate polymer from 0.05%-5%, ammonium hydroxide from 0.1-10%, urea from 0.05 to 5% and water from 30-84%, to be applied on burned skin and surrounding area, to treat an or impede progression and or impede development of burns.
  • a method for inhibiting the rejection of skin implants in a subject in need comprising the step of contact the inflicted area, the surrounding area and/or the implant with an effective amount of the composition of the invention.
  • a method for interfering at the infliction site with production of cytokines, interleukins, tumor necrosis factors, IL1, IL6, TNF comprising the step of contact of the inflicted area, the surrounding area and/or the implant with an effective amount of the composition of the invention.
  • composition and the delivery system described above are refrigerated before or during use.
  • Composition 1 a Carbomer Gelled Matrix Containing Ethanol 35% w/w.
  • Composition 1 was applied to a second degree burn (as a result of short contact with 175° C. hot oven) on the skin of left hand of a 30 years aged female and remained for about one hour. This treatment completely impeded the development of the burn.
  • the preparation was applied and remained on the injury for 20 minutes, on a very thick layer, on the a surface of about 5 centimeters square of the arm of a man aged 35, injured by boiling water.
  • the pain was completely relived after application of the composition in example 7. No vesicles or wound developed after this treatment.
  • Example 5 The composition of Example 5 was applied, to an area larger than the injury, immediately after the burn or one hour after. Following the treatment, the rats were sacrificed and the wound as well as adjacent normal tissues were sampled, fixed, processed by routine technique and stained with hematoxylin & eosin. The progress of the wound was assessed at various times and compared with untreated control groups. The effect of the treatment on preventing the burn progress was evaluated by measuring the burn depth by using a program for evaluation of the vascular network damage and by histological analysis of skin anatomic elements. The data were analyzed by ANOVA test. Animal experiments complied with animal care regulations.
  • FIG. 1 shows histological images of rat skin structures (collagen, epidermis, muscles) after the thermal burn, with ( FIG. 1B -D) and without ( FIG. 1A ) treatment.
  • compositions were applied to the burn skin inflicted as previously described (example 11):
  • Burn progress was assessed by measuring the burn depth by using a program—Galay CUE 2—for evaluation of vascular network damage.
  • the histological burn depth was calculated by measuring the level of blocked and patent vessels within the burn specimens. Histological tissue sections were taken from burn area. The depth of the deepest blocked vessel and that of the most superficial undamaged vessel were measured microscopically from the surface of the burn, using Galay CUE2 advanced software. The resulting values were expressed as a percentage of the total skin thickness, the mean of which was considered to be the percentage depth of the burn. These assessments were made at 3, 6 and 24 hours after the burn. These measurements were expressed as a percentage (%) of the total skin thickness.
  • FIG. 2 demonstrates measurement of depth dermal microvascular destruction in the first 24 hours (at 3, 6 and 24 hours) after burn infliction: Animals have been treated immediate after infliction with carbopol gels containing 20, 30, 50 and 63% w/w ethanol and 1 hour after infliction with the gel containing 30% ethanol. The results are compared with untreated inflicted rats. The depth parameter was measured in rats sacrificed 3, 6, and 24 hours after burn infliction. Results in FIG. 2 show parameters measured at 3, 6 and 24 hours after skin burn: treatment with carbopol gels containing 20-63% w/w ethanol drastically impeded the micro-vascular destruction and progress of burn as compared to untreated rats inflicted animals immediately. Treatment one hour after infliction with 30%w/w ethanolic gel was also very efficient.
  • the parameters investigated included edema formation, inflammation cells migration and preservation of skin structures (epidermis, basal layer, collagen, muscles and appendages). Every histological parameter has been scored using a scale from 0 to 4. Numbers express the balance between the damaged and preserved parameters. A normal parameter is has a score of “0”. With increasing damage, the parameter is represented by higher numbers. Number “4” represents total damage. The sums of all scored parameters express the preservation or destruction of the skin after thermal burn for every treatment. The scored number representing total damage is “28”. These assessments were made at 3, 6 and 24 hours after burn infliction.
  • FIG. 3 shows histological parameters from skin sections 24 hours after burn infliction.
  • the rats were treated immediate after infliction with liquid sprays containing 20, 30, 50 and 70% ethanol.
  • FIG. 4 shows histological parameter from skin sections 24 hours after burn infliction.
  • the rats were treated immediate after infliction with gels containing 20, 30, 50 and 60% w/w ethanol.
  • FIGS. 3 and 4 clearly show that treatment with gels and liquid sprays containing 20 to 70% ethanol stopped burn progression—the most effective gel had a parameter value of 5 as compared with 24 for untreated animals in which the burn wound progressed, and 12 for the most effective spray vs. 22 for untreated progressed burns.
  • compositions containing ethanol and ammonium hydroxide were efficient in impeding the burn development as compared to controls—untreated or aqueous gels treated animals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
US10/791,782 2004-03-04 2004-03-04 Method and composition for burned skin Abandoned US20050196450A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/791,782 US20050196450A1 (en) 2004-03-04 2004-03-04 Method and composition for burned skin
CA002557968A CA2557968A1 (fr) 2004-03-04 2005-03-03 Methode et composition pour le traitement des brulures de la peau
EP05709143.1A EP1720534B1 (fr) 2004-03-04 2005-03-03 Methode et composition pour le traitement des brulures de la peau
PCT/IL2005/000249 WO2005084632A1 (fr) 2004-03-04 2005-03-03 Methode et composition pour le traitement des brulures de la peau
US10/591,687 US20070224272A1 (en) 2004-03-04 2005-03-03 Method and composition for burned skin
JP2007501445A JP5198846B2 (ja) 2004-03-04 2005-03-03 熱傷した皮膚のための方法及び組成物
AU2005219045A AU2005219045B2 (en) 2004-03-04 2005-03-03 Method and composition for burned skin
IL177793A IL177793A (en) 2004-03-04 2006-08-31 Use of ethanol for the preparation of the vehicle for local treatment of burns and such composition
US12/831,349 US8784892B2 (en) 2004-03-04 2010-07-07 Method and composition for burned skin
JP2012172974A JP2012236845A (ja) 2004-03-04 2012-08-03 熱傷した皮膚のための方法及び組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/791,782 US20050196450A1 (en) 2004-03-04 2004-03-04 Method and composition for burned skin

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/591,687 Continuation-In-Part US20070224272A1 (en) 2004-03-04 2005-03-03 Method and composition for burned skin
PCT/IL2005/000249 Continuation-In-Part WO2005084632A1 (fr) 2004-03-04 2005-03-03 Methode et composition pour le traitement des brulures de la peau
US10591687 Continuation-In-Part 2007-06-05

Publications (1)

Publication Number Publication Date
US20050196450A1 true US20050196450A1 (en) 2005-09-08

Family

ID=34911711

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/791,782 Abandoned US20050196450A1 (en) 2004-03-04 2004-03-04 Method and composition for burned skin
US10/591,687 Abandoned US20070224272A1 (en) 2004-03-04 2005-03-03 Method and composition for burned skin
US12/831,349 Expired - Fee Related US8784892B2 (en) 2004-03-04 2010-07-07 Method and composition for burned skin

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/591,687 Abandoned US20070224272A1 (en) 2004-03-04 2005-03-03 Method and composition for burned skin
US12/831,349 Expired - Fee Related US8784892B2 (en) 2004-03-04 2010-07-07 Method and composition for burned skin

Country Status (7)

Country Link
US (3) US20050196450A1 (fr)
EP (1) EP1720534B1 (fr)
JP (2) JP5198846B2 (fr)
AU (1) AU2005219045B2 (fr)
CA (1) CA2557968A1 (fr)
IL (1) IL177793A (fr)
WO (1) WO2005084632A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120297550A1 (en) * 2007-06-12 2012-11-29 Musculoskeletal Transplant Foundation Process for sterilizing acellular soft tissue with irradiation
RU2640026C2 (ru) * 2015-02-16 2017-12-25 Игорь Анатольевич Деев Средство дерматологическое репаративное и способ его наружного применения для ухода за кожей, профилактики и лечения повреждений кожи различной этиологии
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
US10080689B2 (en) 2007-12-06 2018-09-25 Smith & Nephew Plc Wound filling apparatuses and methods
WO2019214838A1 (fr) * 2018-05-09 2019-11-14 Eviderm Institute Ab Utilisation d'une composition contenant de l'alcool pour améliorer la fonction barrière de la peau
CN112121146A (zh) * 2019-06-25 2020-12-25 山东瑞安药业有限公司 一种用于皮肤创伤的外用凝胶剂及其制备方法
US11253399B2 (en) 2007-12-06 2022-02-22 Smith & Nephew Plc Wound filling apparatuses and methods
WO2024011599A1 (fr) * 2022-07-15 2024-01-18 Xantho Biotechnology Co., Ltd Utilisation d'un extrait de coque de fruit de mangoustan dans la préparation d'un médicament pour traiter une brûlure

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015702B1 (ru) * 2007-05-28 2011-10-31 Винченцо Массимо Ломбардо Противовоспалительная и анальгетическая композиция для местного применения в области опорно-двигательного аппарата животного
CL2008000156A1 (es) * 2008-01-18 2008-08-01 Igloo Zone Chile S A Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
MX2012000105A (es) * 2009-06-30 2012-03-14 Univ Columbia Composiciones antimicrobianas/conservadoras que comprenden extractos botanicos.
CA2684258A1 (fr) * 2009-11-03 2011-05-03 Guy Chamberland Compositions contenant des extraits vegetaux et methodes destinees au traitement des blessures, des brulures et des lesions cutanees a l'aide de celles-ci
WO2011087654A1 (fr) 2009-12-22 2011-07-21 Avon Products, Inc. Compositions stimulant la paxilline et leurs utilisations cosmétiques
US20110159125A1 (en) 2009-12-29 2011-06-30 Avon Products, Inc. CGRP Compositions and Uses Thereof
CA2834710A1 (fr) * 2011-05-16 2012-11-22 Dale L. Pearlman Compositions et procedes pour le traitement de maladies de la peau
US10195136B2 (en) 2011-08-24 2019-02-05 Avon Products, Inc. Collagen and elastin stimulating compositions and uses thereof
US8632827B2 (en) 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
GB201207781D0 (en) 2012-05-03 2012-06-13 Restoration Of Appearance And Function Trust Extracellular matrix - synthetic skin scaffold
US20140193529A1 (en) * 2013-01-07 2014-07-10 Avon Products, Inc. Modulation of Thymosin Beta-4 in Skin
TW201422246A (zh) 2012-12-11 2014-06-16 Avon Prod Inc 藉由調節ｗｉｐｉ－１改善皮膚老化外觀之方法
US9168283B2 (en) 2012-12-11 2015-10-27 Avon Products, Inc. Medemia nobilis extracts and methods of use
WO2014093053A1 (fr) * 2012-12-11 2014-06-19 Avon Products, Inc. Modulation de thymosine bêta-4 dans la peau
CN104997837A (zh) * 2014-04-22 2015-10-28 河北盛唐园林科技开发有限公司 一种新型的烫伤药及其制备方法
RU2645115C1 (ru) * 2017-01-12 2018-02-15 ФГБУН Иркутский институт химии имени А.Е. Фаворского Сибирского отделения Российской Академии наук Состав для ускорения заживления ожоговых ран
CN106955277B (zh) * 2017-03-07 2020-02-07 暨南大学 一种含有透明质酸的醇脂质体的透皮给药系统及其制备方法与应用
US9968703B1 (en) 2017-06-15 2018-05-15 Roland C. Schauer Burn wound composition and methods for treating burn wounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013545A (en) * 1987-12-09 1991-05-07 Thames Pharmacal Co., Inc. Aqueous gels containing topical medicaments
AU615901B2 (en) 1988-02-18 1991-10-17 Pharmacia & Upjohn Company Llc Minoxidil gel
JP2675111B2 (ja) * 1988-02-18 1997-11-12 ジ・アップジョン・カンパニー ミノキシジルゲル
ES2012104A6 (es) * 1988-06-28 1990-03-01 Perez Julio Tellez Procedimiento para la extraccion y aislamiento del principio activo regenerador epidermal de la mimosa tenuiflora y composicion cosmetica que lo contiene.
CA1338337C (fr) 1988-09-27 1996-05-21 Health Foundation Limited (The) Methode et composition pour le traitement des brulures
US5093133A (en) 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
JPH04309535A (ja) * 1991-04-05 1992-11-02 Mitsubishi Paper Mills Ltd ゲルフィルム
US5447930A (en) * 1993-05-06 1995-09-05 Warner-Lambert Company Topical anesthetic compositions
JPH0797327A (ja) * 1993-09-29 1995-04-11 Shiseido Co Ltd 火傷用消炎鎮痛剤
JPH07250859A (ja) * 1994-03-12 1995-10-03 Orientetsuku:Kk 人体用冷却剤
US5604200A (en) * 1994-05-02 1997-02-18 Taylor-Mccord; Darlene Wound therapeutic mixture containing medical grade hyaluronic acid and tissue culture grade plasma-fibronectin in a delivery system that creates a moist environment which simulates in utero healing
GB9610862D0 (en) * 1996-05-23 1996-07-31 Evans Brian K Pharmaceutical products
US5958420A (en) * 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
JP2002514220A (ja) * 1997-05-12 2002-05-14 セイジ、ファーマスーティカルズ、インク 熱傷処置および感染防止のための局部スプレー
US6469066B1 (en) 1998-12-18 2002-10-22 Palladin Healthcare International, Ltd. Composition for pain mediation and apparatus and method of use thereof
US6656928B1 (en) * 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
JP4309535B2 (ja) 1999-12-02 2009-08-05 オリオン機械株式会社 除湿装置
DE60142900D1 (de) * 2000-07-07 2010-10-07 Corium Internat Inc Herstellung von hydrophilen druckempfindlichen klebstoffen mit optimalen hafteigenschaften
CA2446060A1 (fr) * 2001-05-07 2002-11-14 Corium International Compositions et systemes d'administration d'un anesthesique local
JP4210914B2 (ja) 2003-05-13 2009-01-21 富士フイルム株式会社 撮像装置

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120297550A1 (en) * 2007-06-12 2012-11-29 Musculoskeletal Transplant Foundation Process for sterilizing acellular soft tissue with irradiation
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
US10080689B2 (en) 2007-12-06 2018-09-25 Smith & Nephew Plc Wound filling apparatuses and methods
US11253399B2 (en) 2007-12-06 2022-02-22 Smith & Nephew Plc Wound filling apparatuses and methods
RU2640026C2 (ru) * 2015-02-16 2017-12-25 Игорь Анатольевич Деев Средство дерматологическое репаративное и способ его наружного применения для ухода за кожей, профилактики и лечения повреждений кожи различной этиологии
WO2019214838A1 (fr) * 2018-05-09 2019-11-14 Eviderm Institute Ab Utilisation d'une composition contenant de l'alcool pour améliorer la fonction barrière de la peau
CN112121146A (zh) * 2019-06-25 2020-12-25 山东瑞安药业有限公司 一种用于皮肤创伤的外用凝胶剂及其制备方法
WO2024011599A1 (fr) * 2022-07-15 2024-01-18 Xantho Biotechnology Co., Ltd Utilisation d'un extrait de coque de fruit de mangoustan dans la préparation d'un médicament pour traiter une brûlure

Also Published As

Publication number Publication date
AU2005219045A1 (en) 2005-09-15
JP2012236845A (ja) 2012-12-06
US8784892B2 (en) 2014-07-22
AU2005219045B2 (en) 2012-01-12
US20070224272A1 (en) 2007-09-27
US20110111010A1 (en) 2011-05-12
JP5198846B2 (ja) 2013-05-15
EP1720534A1 (fr) 2006-11-15
IL177793A (en) 2015-05-31
EP1720534B1 (fr) 2013-09-04
CA2557968A1 (fr) 2005-09-15
IL177793A0 (en) 2006-12-31
WO2005084632A1 (fr) 2005-09-15
JP2007526298A (ja) 2007-09-13

Similar Documents

Publication Publication Date Title
US8784892B2 (en) Method and composition for burned skin
US10653671B2 (en) Topical pharmaceutical compositions for treatment of skin damage
US6645510B1 (en) Method of treating topical ailments
US20180008557A1 (en) Use of two botanicals with complementary activities for improvement of skin
US20130059021A1 (en) Perfluoro(n-butylcyclohexane) compositions and uses thereof
CN103816165B (zh) 一种治疗痤疮的组合物
EP2988731B1 (fr) Composition destinée à être utilisée dans la réduction de la formation de croûtes et favorisant la guérison
EP2739276B1 (fr) Composition antiseptique
US20030104018A1 (en) Skin product having micro-spheres, and processes for the production thereof
KR20110096054A (ko) 과불화탄소 겔 배합물
CA3044944A1 (fr) Film buccal hemostatique et de protection des plaies
US20030026819A1 (en) Cream-to-powder dermatological composition
US20050123576A1 (en) Mupirocin compositions for topical use, an improved process of making same and methods of using same
AU2007293500A1 (en) Medicine for the treatment of acne and for reversing the signs of age and sun damage and method for using same
US6562326B1 (en) Topical composition for burn healing
US8529966B2 (en) Burn treatment composition and method
EP1453526B1 (fr) Composition pharmaceutique pour le traitement topique d'affections cutanees et de lesions cutanees
Babickaite et al. Therapeutic activity of chlorhexidine-poloxamer antiseptic gel on wound healing in rats: a preclinical study
NZ606177A (en) Compositions for the treatment of actinic keratosis
EP2299815A1 (fr) Procédé de traitement de brûlures mettant en oeuvre un composé d avermectine
US20230302028A1 (en) Pain-relieving topical compositions
EP2845591A1 (fr) Utilisation d'acide trifluoroacétique en tant qu'agent kératolytique afin de traiter les lésions cutanées hyperkératosiques

Legal Events

Date Code Title Description
AS Assignment

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TOUITOU, ELKA;REEL/FRAME:015049/0403

Effective date: 20040301

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION